Meg Jardine's Publications

• Angiotensin receptor blockers for the treatment of covid-19: Pragmatic, adaptive, multicentre, phase 3, randomised controlled trial

  Journal articles

  2022

  BMJ

• Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial

  Journal articles

  2022

  Journal of Diabetes Research

• Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to Action

  Journal articles

  2022

  Canadian Journal of Kidney Health and Disease

• Renal, cardiovascular and safety outcomes of canagliflozin in patients with type2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial

  Journal articles

  2022

  Journal of Diabetes Investigation

• Sex and Gender Considerations in Randomized Controlled Trials in Adults Receiving Chronic Dialysis: A Meta-Epidemiologic Study

  Journal articles

  2022

  Journal of the American Society of Nephrology

• INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-7 PREDICTS CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: THE CREDENCE TRIAL

  Journal articles

  2022

  Journal of the American College of Cardiology

• POS-527 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)

  Conference Posters

  2022

• POS-019 A NOVEL RISK PREDICTION MODEL FOR SERVE ACUTE KIDNEY INJURY IN INTENSIVE CARE UNIT PATIENTS RECEIVING FLUID RESUSCITATION

  Conference Abstracts

  2022

  Kidney International Reports

• Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial

  Journal articles

  2021

  European Heart Journal

• The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics

  Journal articles

  2021

  American Journal of Nephrology

• Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial

  Journal articles

  2021

  Trials

• Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis

  Journal articles

  2021

  Diabetes, Obesity and Metabolism

• Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbAinf1cinf, disease duration and treatment intensity: results from the CANVAS Program

  Journal articles

  2021

  Diabetologia

• Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

  Journal articles

  2021

  European Heart Journal

• Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

  Conference Papers

  2021

  EUROPEAN HEART JOURNAL

• Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial

  Journal articles

  2021

  Clinical Journal of the American Society of Nephrology

• ANTIPLATELET AGENTS FOR CHRONIC KIDNEY DISEASE: AN UPDATED COCHRANE REVIEW

  Conference Papers

  2021

  NEPHROLOGY

• MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL

  Conference Papers

  2021

  NEPHROLOGY

• Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis

  Journal articles

  2021

  Hemodialysis International

• Canagliflozin, serum magnesium and cardiovascular outcomesAnalysis from the CANVAS Program

  Journal articles

  2021

  Endocrinology, Diabetes and Metabolism

• The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

  Conference Abstracts

  2021

  Diabetes, Obesity and Metabolism

• Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

  Journal articles

  2021

  DIABETES

• The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

  Journal articles

  2021

  DIABETES

• Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE

  Journal articles

  2021

  DIABETES

• Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

  Journal articles

  2021

  Diabetes, Obesity and Metabolism

• Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial

  Journal articles

  2021

  Circulation